| 3 -0.12 (-3.85%) | 03-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.13 | 1-year : | 4.82 |
| Resists | First : | 3.53 | Second : | 4.13 |
| Pivot price | 2.32  |
|||
| Supports | First : | 2.33 | Second : | 1.59 |
| MAs | MA(5) : | 3.04 |
MA(20) : | 2.17 |
| MA(100) : | 1.73 |
MA(250) : | 1.63 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 80.1 |
D(3) : | 86.8 |
| RSI | RSI(14): 71.5 |
|||
| 52-week | High : | 3.53 | Low : | 0.99 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MGNX ] has closed below upper band by 20.4%. Bollinger Bands are 428.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.24 - 3.26 | 3.26 - 3.28 |
| Low: | 2.93 - 2.95 | 2.95 - 2.97 |
| Close: | 2.97 - 3 | 3 - 3.03 |
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Sat, 14 Mar 2026
MacroGenics (NASDAQ:MGNX) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Thu, 12 Mar 2026
MGNX: Multiple clinical milestones and strategic updates expected in 2026, backed by strong partnerships - TradingView
Wed, 11 Mar 2026
MacroGenics (MGNX) Loss Of US$74.6 Million Tests Bullish Loss‑Narrowing Narrative - Sahm
Tue, 10 Mar 2026
Barclays Raises Price Target for Macrogenics (MGNX) to $4.00, Ma - GuruFocus
Mon, 09 Mar 2026
MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Mon, 09 Mar 2026
MacroGenics: Q4 Earnings Snapshot - KING5.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 63 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 3 (%) |
| Held by Institutions | 64.8 (%) |
| Shares Short | 4,220 (K) |
| Shares Short P.Month | 4,040 (K) |
| EPS | -1.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.05 |
| Profit Margin | -59.5 % |
| Operating Margin | 25.5 % |
| Return on Assets (ttm) | -26.6 % |
| Return on Equity (ttm) | -81.2 % |
| Qtrly Rev. Growth | -34.3 % |
| Gross Profit (p.s.) | -0.89 |
| Sales Per Share | 2.01 |
| EBITDA (p.s.) | -1.68 |
| Qtrly Earnings Growth | -70.5 % |
| Operating Cash Flow | -162 (M) |
| Levered Free Cash Flow | -125 (M) |
| PE Ratio | -2.48 |
| PEG Ratio | 0 |
| Price to Book value | 2.83 |
| Price to Sales | 1.48 |
| Price to Cash Flow | -1.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|